Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
June 29, 2023 07:00 ET
|
Genelux Corporation
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec...
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
June 22, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that it will be added to the...
Genelux Corporation Announces $18 Million Private Placement
June 12, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
May 25, 2023 16:01 ET
|
Genelux Corporation
Phase 2 Trial of Olvi-Vec-primed immunochemotherapy in heavily pre-treated patients Met primary endpoint of objective response rate with deep and durable responsesGenerated promising...
Genelux Corporation Announces $33 Million Private Placement
May 15, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares...
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
March 23, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX) (“Genelux” or “the Company”), a late clinical-stage biopharmaceutical company focused on developing a...
Genelux Corporation Announces Pricing of Initial Public Offering
January 25, 2023 21:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux” or “the Company”), a clinical-stage immunotherapy company focused on developing a pipeline of...
Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
September 21, 2022 08:06 ET
|
Genelux Corporation
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapy Trial will be conducted as a collaboration between Genelux and The...
Genelux Initiates Two Clinical Trials of GL-ONC1 in Ovarian Cancer and Solid Organ Cancers with Leading Oncology Institutions
July 28, 2016 08:00 ET
|
Genelux Corporation
First two patients dosed in Phase 1b Trial in Ovarian Cancer at Florida Hospital Cancer Institute (FHCI) First three patients dosed in Phase 1b Trial in Solid Organ Cancers at Moores Cancer Center at...
Genelux Announces Promising Data From Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma
May 27, 2015 08:00 ET
|
Genelux Corporation
Data Demonstrate Favorable Safety Profile and Anti-Tumor Activity
Results to be Presented at ASCO Annual Meeting 2015 During Two Poster Presentations
SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) --...